- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11.25 | NSE - LakeShore Biopharma Co., Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| 04.11.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.09.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.09.2025 | 992 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 30.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.09.2025ISIN NameCA8875221001 TINKA... ► Artikel lesen | |
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 22.09.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting | 218 | PR Newswire | BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 12.09.25 | LakeShore Biopharma faces Nasdaq delisting after failing to meet bid price rule | 2 | Investing.com | ||
| 12.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq | 853 | PR Newswire | BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 10.09.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.09.25 | LakeShore Biopharma appoints advisors to evaluate buyout proposal | 1 | Investing.com | ||
| 29.08.25 | LakeShore Biopharma Board Reviewing Revised $0.86-Per-Share Buyout Proposal | - | RTTNews | ||
| 28.08.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee | 506 | PR Newswire | BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 18.08.25 | LakeShore Biopharma receives $0.86/share buyout proposal from Oceanpine Capital | 2 | Seeking Alpha | ||
| 18.08.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.08.25 | Oceanpine Capital unterbreitet Übernahmeangebot für LakeShore Biopharma zu 0,86 US-Dollar je Aktie | 1 | Investing.com Deutsch | ||
| 18.08.25 | Oceanpine Capital proposes to acquire LakeShore Biopharma for $0.86 per share | 1 | Investing.com | ||
| 18.08.25 | LakeShore Biopharma Receives Proposal Letter From Oceanpine Capital | 1 | RTTNews | ||
| 18.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company | 201 | PR Newswire | BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 01.08.25 | LakeShore Biopharma GAAP EPS of -RMB5.22, revenue of RMB615M | 1 | Seeking Alpha | ||
| 31.07.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Fiscal Year 2025 Financial Results | 120 | PR Newswire | Total revenue reached RMB615.0 million, representing 7.2% year-over-year growth
Gross profit rose to RMB507.2 million, up 11.3% year-over-year
Gross margin improved... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 317,25 | +6,55 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,14 | -3,41 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 72,51 | -0,12 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 88,64 | +4,26 % | Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why | ||
| ADMA BIOLOGICS | 17,310 | -1,09 % | ADMA Biologics, Inc. (ADMA): A Bull Case Theory | ||
| BEAM THERAPEUTICS | 31,220 | -2,59 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| ERASCA | 9,625 | +0,68 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| CG ONCOLOGY | 54,73 | +3,13 % | CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why | ||
| JANUX THERAPEUTICS | 13,760 | +0,29 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TANGO THERAPEUTICS | 13,010 | +11,29 % | Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data | ||
| IMMUNOME | 22,410 | -1,93 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| QIAGEN | 39,255 | -3,83 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 10,160 | -3,24 % | Day One Biopharmaceuticals stock initiated with Buy rating at TD Cowen | ||
| AMYLYX PHARMACEUTICALS | 14,300 | +5,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,350 | -3,67 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen |
LAKESHORE BIOPHARMA CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,665 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.